Application of demethylase ALKBH5 in neuroinflammation after traumatic brain injury
By regulating m6A demethylase ALKBH5, it inhibits the inflammatory response of microglia, solves the problem of difficult control of neuroinflammatory response after traumatic brain injury, promotes neurologic repair and prognosis, and provides new for TBI patients Therapeutic target.
Patent Information
- Application Number
- CN202411159348.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-29
AI Technical Summary
Excessive inflammatory activation of microglia after traumatic brain injury makes it difficult to control the neuroinflammatory response, hindering the repair and prognosis of neurological functions. The existing treatments lack targeted and root causes.
By regulating the expression and activity of m6A demethylase ALKBH5, inhibiting the inflammatory response of microglia, the microglia-specific ALKBH5 gene knockout model was constructed by regulating the expression and activity of m6A demethylase ALKBH5, and the inflammatory response of microglia was inhibited. The ALKBH5 recombinant protein or CRISPR/Cas9 gene editing technology was used to construct a microglia-specific ALKBH5 gene knockout model, and the study of its Role in neuroinflammation after traumatic brain injury.
It effectively inhibits the excessive inflammatory activation of microglia, affects the disease evolution process after traumatic brain injury, promotes neurological repair and prognosis, and provides new therapeutic targets for TBI patients.
Smart Images

Figure CN119033936A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to application of demethylase ALKBH5 in neuroinflammation after traumatic brain injury, and belongs to the technical field of biomedicine. Background Art
[0002] Traumatic brain injury (TBI) has become a prominent public health and socioeconomic problem in many countries around the world due to its high incidence, mortality and disability rates, and is recognized as the leading cause of death among young adults under the age of 45. Currently, the mortality rate of severe TBI can be as high as 35%, and the incidence of neurological dysfunction after injury remains high, bringing long-term economic burden and severe mental stress to the injured and their families.
[0003] TBI is a complex pathological transformation process, which can be roughly divided into the following two stages: ① Primary brain injury: direct mechanical stress injury suffered by the brain parenchyma at the moment of traumatic impact. The severity of this type of injury mainly depends on external factors such as the size and nature of the initial force, the direction of impact and the site of injury. ② Secondary brain injury: a series of secondary pathological and physiological changes in brain tissue and cells caused by primary injury, such as intracranial hemorrhage, brain tissue and cell edema, intracranial hypertension, blood-brain barrier damage, oxidative stress and neuroinflammation. Secondary brain injury can occur within a few minutes after injury, with varying durations, and has significant cascade reactions and superposition effects, which can lead to further aggravation of the condition on the basis of the original injury and even induce new pathological changes. Although neuroimaging technology has made great progress in recent years, coupled with the popularization of multimodal monitoring applications, neurosurgeons can make more timely and accurate judgments on the condition of TBI patients and choose surgical plans such as intracranial hemorrhage and malignant intracranial hypertension, which has reduced the acute mortality rate of TBI patients to a certain extent. However, these efforts are only remedial treatment measures for the consequences of primary injury. However, for primary brain injury and the secondary pathological damage to the brain parenchyma caused by it, especially the neuroinflammatory response induced by TBI, most people choose symptomatic palliative treatment. At present, there is still a lack of accurate and targeted clinical treatment methods. The neuroinflammatory response mediated by microglia after TBI exists almost throughout the entire pathological change stage after brain injury, and it cannot be effectively curbed from the root. This has always been the "Achilles heel" of TBI treatment strategies and one of the core issues that hinder the repair of neurological function in TBI patients.
[0004] Microglia, as a type of immune cell inherent in the central nervous system (CNS), account for about 10-15% of the total adult CNS cells. This type of cell has extremely high plasticity and adaptability, and can show different regulatory functions according to the different developmental stages of the nervous system, regional distribution characteristics, and health or disease states. Studies have found that microglia are also the main regulators and "trigger points" of neuroinflammatory responses after TBI. At the beginning of a TBI event, damaged neurons or proteins will release damage-associated molecular patterns (DAMPs) and ATP into the interstitial space, and microglia resident in the periphery of the area will quickly sense these changes and enter an activated state. Their radial cell processes gradually transform into spherical amoeboid terminals, mobilizing and migrating to the damaged area to phagocytose debris and promote myelin regeneration. At the same time, activated microglia will trigger a large number of inflammatory cascades, stimulate astrocyte activation, induce damaged neurons to initiate cell death programs, and increase the permeability of the blood-brain barrier. For TBI events, the above effects are conducive to the early removal of necrotic tissue in the injured area, which is a necessary condition and prerequisite for self-repair of CNS tissue after damage, and is an important innate immune defense response. However, if this "trigger point" is continuously and uncontrolled over-activation, it will bring about a completely opposite "negative effect" to the subsequent repair process.
[0005] Further studies have confirmed that the release of cytokines induced by traumatic stimuli such as TBI events will not only cause inflammatory activation of microglia. At the same time, it will also stimulate the activation of inflammatory-related signaling pathways such as NFκB / NLRP3 and ERK / MAPK in microglia, forming a "positive feedback" regulatory loop, exacerbating the further activation of microglia until the cells appear in a "disinhibited" state after activation, and inflammatory factors and cytotoxic mediators are continuously released at high levels, thereby inducing delayed repair and destruction of the blood-brain barrier, and even causing irreversible neuronal death and other malignant consequences. This dysregulated microglial activation can persist in the brain tissue of TBI patients for up to 17 years, and the inflammatory factors secreted by them (such as IL-6, TNF-α and MHC-II, etc.) are significantly negatively correlated with the long-term survival prognosis of patients with moderate to severe TBI. Therefore, there is a long-term and excessive inflammatory response in the brain tissue after TBI, and microglia play an important role in it. How to effectively curb excessive inflammatory activation in microglia and explore its potential regulatory mechanism is expected to become a key "breakthrough" in the current treatment of neuroinflammatory response after TBI. At the same time, the discovery of new protection and treatment strategies will help reduce the mortality and disability rates of TBI patients, which is of great significance to improving the survival prognosis of patients.
[0006] Epigenetics refers to the genetic mechanism that local structural modifications are made to DNA, RNA, histones and chromatin without changing the genomic DNA sequence, resulting in heritable changes in gene expression, which leads to phenotypic variation and ultimately affects cell differentiation and development and functional changes. Current studies have confirmed that epigenetic modifications play an important regulatory role in the structural development of the nervous system and the occurrence and development of related diseases. Among them, N6-adenylate methylation (m6A), that is, the methylation modification on the sixth nitrogen atom of adenine in RNA molecules, is the most common type of epigenetic modification on eukaryotic RNA. It is involved in almost every link of RNA metabolism, including mRNA stability, shearing, induction of nuclear and translation regulation, and biosynthesis of lncRNA and miRNA. In the development of the nervous system of humans and other mammals, more than 25% of RNA transcriptome-level regulation has m6A modification. Currently, the proteins known to be involved in the regulation of m6A modification mainly include the following three categories: ① Methyltransferase: “Writers”, enzymes that catalyze the production of methylation modifications on RNA, representative genes include METTL3 / 14, WATP, etc.; ② Demethylase: “Erasers”, enzymes responsible for removing methylation modifications, representative genes include FTO, ALKBH5, etc.; ③ Methylation Binding Protein: “Readers”, responsible for identifying methylation modification sites and binding to them, adjusting RNA structure, improving transcription and translation efficiency or inducing their degradation, representative genes include YTHDF1-3, etc.
[0007] With the continuous deepening of relevant research, the relationship between RNA-m6A modification and nervous system-related diseases has also gradually attracted attention. Some literature has found that there is a significant high expression of METTL3 in the hippocampus of brain tissue in rats with Alzheimer's disease model, which may be related to the hyperphosphorylation of tau protein. In the cerebral ischemia-reperfusion injury model, FTO can effectively reduce the RNA methylation level of BCL-2, stabilize its transcription and translation process, and enhance the anti-apoptosis ability of neurons. YTHDF1 can affect its mRNA degradation process by binding to the methylation recognition site at the transcription level of NF-κB, thereby exerting an inflammatory inhibitory effect. In TBI-related research, although some scholars have carried out exploratory bioinformatics analysis based on m6A high-throughput sequencing technology, it only proves that there may be changes in the level of transcriptome m6A modification after TBI, and has not made targeted in-depth research on its cell subtype localization and specific regulatory functions. Summary of the invention
[0008] The purpose of the present invention is to address the technical problem that the neuroinflammatory response of microglia after TBI is one of the main pathological changes of secondary injury, which exists in almost the entire pathological change stage after brain injury and cannot be effectively controlled from the root. The present invention provides the use of m6A demethylase ALKBH5 in neuroinflammation caused after TBI; the present invention confirms for the first time that m6A demethylase ALKBH5 can inhibit the excessive neuroinflammatory response of microglia, thereby affecting the disease evolution process of TBI patients and promoting the neurological function repair and prognosis of TBI patients. The present invention provides a new potential therapeutic target for neuroinflammation after traumatic brain injury.
[0009] In order to achieve the above object, the present invention adopts the following technical solutions:
[0010] In a first aspect, the present invention provides the use of demethylase ALKBH5 as a target in the preparation or screening of drugs for treating neuroinflammation after traumatic brain injury.
[0011] Optionally, the application includes: use of a substance that specifically promotes or activates the expression or activity of ALKBH5 in the preparation of a drug for treating neuroinflammation after traumatic brain injury.
[0012] Optionally, the substance that promotes or activates the expression or activity of ALKBH5 includes ALKBH5 recombinant protein, a nucleic acid molecule that can specifically increase the expression of the ALKBH5 gene, and a recombinant vector or recombinant bacteria containing the nucleic acid molecule.
[0013] Optionally, the drug targets microglia.
[0014] The second aspect of the present invention provides a method for experimentally verifying the use of ALKBH5 in inhibiting neuroinflammation after traumatic brain injury or down-regulating the expression of ALKBH5 in microglia in promoting neuroinflammation after traumatic brain injury for non-diagnostic treatment purposes, comprising the following steps:
[0015] Step 1. Detect the expression of ALKBH5 and the m6A modification level of the transcriptome: Western blot was used to detect the differentially expressed proteins in the TBI-injured cortical tissue at different time points after the TBI mouse model was established, and Dot blot was used to detect the m6A modification level of the transcriptome in the TBI-injured cortical tissue at different time points after the model was established;
[0016] Step 2. Single-cell sequencing analysis of ALKBH5 expression and localization: Analyze the transcriptome single-cell sequencing results of damaged cortical tissue at different time points after TBI mouse model establishment to detect the expression and localization of ALKBH5 in TBI damaged cortical tissue;
[0017] Step 3. Detect the regulatory effect of ALKBH5 on microglial inflammation induced by traumatic brain injury: Use lipopolysaccharide (LPS) drug treatment to construct an inflammatory activation model of BV2 cell line, rat and mouse primary microglia in vitro, then knock down the expression of ALKBH5 in microglia by siRNA, and observe the biological activity of ALKBH5 under different treatment conditions and its regulatory function on microglial inflammation;
[0018] Step 4. Detect in animals the promoting effect of microglia-specific ALKBH5 gene knockout on neuroinflammation after TBI: construct microglia-specific ALKBH5 gene knockout mice by CRISPR / Cas9 gene editing technology, and use mice without ALKBH5 expression as negative control group. After TBI modeling was established in both groups of mice, the neurobehavioral function of the mice after modeling, the damage of the cortical tissue of the mice at different time points after modeling, the overall pathological changes of the continuous coronal sections of the mouse brain tissue tar violet staining, and the leakage of EB dye in the cortical tissue of the mice at different time points after modeling were detected.
[0019] Optionally, the method for constructing a microglia-specific ALKBH5 gene knockout mouse in step 5 comprises: after analyzing the structure of ALKBH5, selecting the transcript of the ALKBH5 gene Transcript ID-ENSMUST00000044250.4, inserting LoxP (locus of X-over P1) Cre enzyme cleavage sites at both ends of the exon1-exon2 region using CRISPR / Cas9 gene editing technology, and obtaining a homozygous ALKBH5 with two loxP sites by heterozygous interpairing. flox / flox Mice, and then homozygous ALKBH5 flox / flox Mice with microglia-specific CX3CR1-Cre ERT2 The tool mice were mated and bred, and tamoxifen was induced to finally obtain microglia-specific ALKBH5 gene knockout mice ALKBH5 MG-KO .
[0020] In a third aspect of the present invention, a microglia-specific ALKBH5 gene knockout mouse model is provided for use in studying the regulatory effect of ALKBH5 on neuroinflammation after traumatic brain injury and in constructing a model for studying the function of the ALKBH5 gene. The method for constructing the ALKBH5 gene knockout mouse model comprises: after analyzing the structure of ALKBH5, selecting the transcript Transcript ID-ENSMUST00000044250.4 of the ALKBH5 gene, inserting Loxp (locus of X-over P1) Cre enzyme cleavage sites at both ends of the exon1-exon2 region using CRISPR / Cas9 gene editing technology, and obtaining a homozygous ALKBH5 with two loxP sites by heterozygous intermatching. flox / flox Mice, and then homozygous ALKBH5 flox / flox Mice with microglia-specific CX3CR1-Cre ERT2 The tool mice were mated and bred, and tamoxifen was induced to finally obtain microglia-specific ALKBH5 gene knockout mice ALKBH5 MG-KO .
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] In view of the problem that the neuroinflammatory response of microglia after TBI is one of the main pathological changes of secondary injury, which exists almost in the entire pathological change stage after brain injury and cannot be effectively curbed from the root, the present invention takes the change of m6A modification level in the transcriptome of damaged cortical tissue after TBI as the entry point, and confirms for the first time that the m6A demethylase ALKBH5 can inhibit the excessive neuroinflammatory response of microglia, thereby affecting the disease evolution process of TBI patients and promoting the neurological function repair and prognosis of TBI patients; the present invention provides a new therapeutic target for effectively curbing the excessive neuroinflammatory response of microglia after TBI and promoting the neurological function repair of TBI patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 .Detection of m6A modification levels and key regulatory proteins in damaged cortical tissues of mice after TBI: (A) Western blot detection results of key regulatory proteins of m6A modification in damaged cortical tissues at different modeling time points. Compared with the sham operation group (Sham), the expression of demethylase ALKBH5 in TBI damaged cortical tissues gradually increased over time, and ACTIN was used as an internal reference; (B) Dot blot detection results of m6A modification levels in the transcriptome of damaged cortical tissues at different modeling time points. Compared with the sham operation group (Sham), the m6A modification levels in the transcriptome of TBI damaged cortical tissues decreased over time.
[0024] Figure 2 m6A demethylase ALKBH5 may regulate microglial activation induced by traumatic brain injury: (A) Schematic diagram of single-cell sequencing results of damaged cortical tissue after CCI modeling in mice. The cortical tissues of the damaged area were collected from the sham operation group (Sham, n=3), the first day after injury (TBI-1, n=4), the third day (TBI-3, n=2), the seventh day (TBI-7, n=3) and the fourteenth day (TBI-14, n=4) after modeling, and the number of cells captured at different time points was analyzed by single-cell sequencing; (B) Cells were analyzed by the expression results of cell-specific gene markers Results of tSEN dimensionality reduction analysis after type identification; (C) t-SNE dimensionality reduction distribution diagram of transcriptome expression of ALKBH5 at the single-cell level; (D) Violin analysis diagram of transcriptome expression of ALKBH5 at the single-cell level; (E) Immunofluorescence co-localization staining results of ALKBH5 with neuron-specific marker NEUN, astrocyte-specific marker GFAP, and microglia-specific marker IBA1. The Sham group selected the edge of the normal cortical tissue of the sham operation group for photography, and the TBI group selected the relatively intact area of the inner cell structure of the damaged cortical tissue and the edge of the damaged cortical tissue for photography.
[0025] Figure 3.ALKBH5 can regulate microglia-mediated neuroinflammatory response: (A) Western blot test results showed that after in vitro lipopolysaccharide (50ng / ml, LPS) drug treatment, the expression of ALKBH5 in BV2 cell line, mouse and rat primary microglia increased to varying degrees, and ACTIN was used as an internal reference control; (B) siRNA downregulated the expression of ALKBH5 in BV2 cell line, mouse and rat primary microglia, and CCK-8 was used to detect cell activity; (C) After in vitro LPS drug treatment for 6 hours, siRNA downregulated the expression of ALKBH5 in BV2, mouse and rat primary microglia for 36 hours, and western blot was used to detect cell activity. Blot was used to detect the changes in ALKBH5 protein levels, and ACTIN was used as an internal reference control; (D) After in vitro LPS drug treatment combined with siRNA down-regulating ALKBH5 expression, Dot-blot was used to detect the changes in m6A modification levels in BV2 cell lines, primary microglia of mice and rats. Methyl blue staining was used as a quality control reference to normalize the total RNA content; (E) After in vitro LPS drug treatment combined with siRNA down-regulating ALKBH5 expression, the three types of microglia were immunofluorescently double-stained with IBA1 (red) and ALKBH5 (green), and the cell nuclei were confirmed by DAPI (blue) staining, Scale bar = 20 or 25μm; (F) After in vitro LPS drug treatment combined with siRNA down-regulating ALKBH5 expression, Real-time analysis of the changes in the relative expression levels of inflammatory factor mRNA in the three types of microglia before and after intervention PCR detection, siALKBH5-1 / 2 was used for the regulation of mouse ALKBH5 gene expression, and siALKBH5-3 / 4 was used for the regulation of rat ALKBH5 gene expression; *P<0.05, **P<0.01, ***P<0.001vs.Control; #P<0.05, ##P<0.01, ###P<0.001vs.LPS group.
[0026] Figure 4 . Specific knockout of ALKBH5 expression in microglia aggravates nervous system damage and delays recovery of neurobehavioral function in CCI mice: (A) Microglia-specific ALKBH5 gene knockout mouse breeding strategy. ALKBH5 has two transcripts. After analyzing its structure, CRISPR / Cas9 gene editing technology was used to insert Loxp (locus of X-over P1) Cre enzyme cleavage sites at both ends of the exon1-exon2 region, and homozygous (ALKBH5) with two loxP sites was obtained by heterozygous mating. flox / flox ) mice, and then transfected with microglia-specific CX3CR1-Cre ERT2The tool mice were mated and bred, and tamoxifen was induced to finally obtain microglia-specific ALKBH5 gene knockout mice (ALKBH5 MG-KO ); the negative control mice were selected with CreER allele deletion (ALKBH5 MG-Con ) offspring mice; (B) Overview of in vivo experiments and neurobehavioral testing time; (C) Comparison of cortical tissue damage in mice at different time points after CCI modeling, showing that ALKBH5 was upregulated at 7 days (TBI-7) and 14 days (TBI-14) after modeling. MG-KO Cortical tissue damage and repair in mice compared with ALKBH5 MG-Con The cavitation-like loss of local cortical tissue was more obvious in the model mice group. (D) Gross pathological changes of the brain tissue of the model mice in the coronal sections stained with tar violet. Compared with the contralateral cortex tissue, ALKBH5 MG-KO The Ipsilateral Cortex of mice was significantly more missing than that of the control group (ALKBH5 MG-Con ) is more obvious, N = 8 / group; (E) Comparison of EB dye leakage (Extravasation) in mouse cortical tissue at different time points after modeling. The blue area represents the location of dye leakage. The statistical results show that ALKBH5 MG-KO The repair of the blood-brain barrier in the injured cortical tissue of mice was delayed, and the leakage of EB dye was more severe than that of ALKBH5 MG-Con The difference was more obvious in the 42-h group (N=8 / group); (FI) The neurobehavioral function scores of mice at different time points after modeling, including mNSS scores (F), Rotarod test (G), Hanging Wire test (H) and Grip Strength Test (I).
[0027] Figure 5 . Loss of ALKBH5 expression in microglia aggravates gait dysfunction in the contralateral limbs of CCI-induced mice: (AD) ALKBH5 MG-KO Mouse, ALKBH5 MG-Con The statistical results of basic movement data of mice and their sham-operated counterparts in gait detection analysis showed that after CCI modeling, ALKBH5 MG-KO ALKBH5 MG-ConCompared with the sham operation group, the number of steps per unit time (A), walking speed (B), the distance traveled by the left limb between two consecutive starting postures (C), and the distance traveled by the right limb between two consecutive starting postures (D) of the mice showed obvious functional decline, but there was no significant statistical difference between the two groups of model mice; (E) Statistical results of footprint pressure data in gait detection analysis of the four groups of mice, ALKBH5 MG-KO The footprint pressure of mice after modeling was compared with ALKBH5 MG-Con The mice were significantly weakened; (F) The footprint pressure heat map analysis results of the four groups of mice in the gait detection analysis showed that ALKBH5 MG-KO Mice and ALKBH5 MG-Con The footprint pressure of the left limb of mice was significantly weaker than that of the right limb; (GJ) The results of the left forelimb gait test and analysis of the four groups of mice showed that ALKBH5 MG -KO The average footprint pressure (G), average contact area with the ground (H), and maximum contact area between a single foot and the ground (J) of the left forelimb of mice after modeling were compared with those of ALKBH5 MG-Con The gait analysis results of the left hind limbs of the four groups of mice showed that ALKBH5 MG-KO The average footprint pressure (K) of the left hind limb of mice after modeling, the average contact area with the ground (L), and the maximum pressure of a single footprint (M) were compared with ALKBH5 MG-Con There was no significant statistical difference in the mice, but the maximum contact area (N) between the left hind limb and the ground was higher than that of ALKBH5 MG-Con Mice were weakened. DETAILED DESCRIPTION
[0028] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.
[0029] The experimental methods in the following examples without specifying specific conditions were carried out according to conventional methods and conditions, or selected according to the product instructions; the materials, reagents, etc. used were conventional commercially available products unless otherwise specified.
[0030] Example
[0031] This example provides the use of demethylase ALKBH5 in neuroinflammation after traumatic brain injury:
[0032] 1. Experimental methods and materials
[0033] 1. Creation of the Controlled Cortical Impact (CCI) Model in Mice
[0034] Controlled Cortical Impact is a model of TBI. Male C57BL / 6J mice (provided by Shanghai Slake Experimental Animal Co., Ltd., 8-10 weeks old, weighing 20-25g) were used. 0.6% pentobarbital solution, 80mg / kg, was intraperitoneally injected to anesthetize the mice; the mice were fixed in a stereotaxic apparatus (Stoeling Inc.USA); a midline incision was made at the junction of the lambdoid suture and the sagittal suture after 75% alcohol, the scalp was separated, and the periosteum was peeled off; a hole was drilled in the skull between the right coronal suture and the lambdoid suture, 1.5-2mm away from the midline, with a bone window of about 4mm in diameter, to expose the complete dura mater; PinPoint was used to TM The PCI3000 precision cranial impact instrument (Hatteras Instruments Inc. USA) was used to set the impact parameters, and a 3mm diameter impact head was used to accurately impact the mouse cerebral cortex. Among them, the experimental impact depth was 1.5mm; the impact time was 100ms; and the impact speed was 1.5m / s. After the injury, cotton balls were used to stop bleeding, bone wax was used to seal the skull defect, and 6-0 silk thread was used to suture the scalp. The 37℃ temperature-controlled blanket was used to keep the mice warm until they fully woke up. After anesthesia, the bone window was exposed in the sham operation group, and the cerebral cortex was not impacted. The bone flap was then returned and the scalp was sutured.
[0035] 2. Collection of Mouse Brain Tissue Samples
[0036] After the mice are anesthetized, the chest is opened to expose them sufficiently for cardiac puncture and cutting of the right atrial appendage. The perfusion needle is inserted into the apex of the heart, the right atrial appendage is cut open, and the venous blood is opened. First, about 20 mL of normal saline is perfused, and when the mouse liver turns white, about 15 mL of 4% paraformaldehyde is perfused instead. The sign of successful perfusion is: the mouse's forelimbs twitch violently at the beginning of perfusion, and the forelimbs and neck are stiff. After the perfusion is completed, the skin is cut to expose the head and neck segment, and the cervical cord is cut from the cervical vertebrae; the posterior neck muscles are separated and removed, and the skull is carefully removed with curved forceps. When separating the skull, pay attention to the dura mater to avoid scratching the brain tissue with the dura mater; when taking the brain, start from the medulla oblongata and slowly separate the skull base tissue to reduce damage to the brain.
[0037] 3. Western Blot Detection of Mouse Brain Tissue and Cells
[0038] Total protein was extracted from cell lysate, and the protein concentration in the lysate was quantified using an enhanced BCA protein assay kit. The loading amount was determined based on experimental requirements and target protein expression, and a color pre-stained protein molecular weight standard was used to determine the molecular weight. The electrophoresis instrument was initially set to 80V electrophoresis, and the voltage was adjusted to 120V when the sample reached the separation gel until bromophenol blue reached the bottom of the gel, the electrophoresis was stopped, and the separation gel was cut off. The PVDF membrane (pre-activated with methanol) and two filter papers were cut according to the size of the gel, and immersed in the transfer buffer to make a sandwich structure arranged as (-) pole / sponge pad / filter paper / gel / PVDF membrane / filter paper / sponge pad (+), and placed in the transfer tank, with a constant current of 300mA, and electrotransferred for 45-60min according to the molecular weight of the protein. After the transfer, the PVDF membrane was immersed in the blocking solution, blocked at room temperature for 1 hour, and incubated with the corresponding primary antibody at 4°C overnight; the next day, the primary antibody was recovered and the membrane was washed 3 times with TBST, each time for 10 minutes; the corresponding species secondary antibody was added, incubated at room temperature for 1 hour, washed 3 times with TBST, each time for 10 minutes, and then the ECL color reaction was performed.
[0039] Antibody reagents used are as follows:
[0040] METTL14(D8K8W)Rabbit mAb#51104,CST;
[0041] METTL3(E3F2A)Rabbit mAb 86132,CST;
[0042] Anti-FTO antibody [5-2H10] (ab92821), Abcam;
[0043] WTAP Antibody #56501, CST;
[0044] Recombinant Anti-ALKBH5 antibody [EPR18958] (ab195377), Abcam;
[0045] GAPDH Monoclonal antibody,Proteintech;
[0046] Recombinant Anti-PDGFR alpha antibody [EPR22059-270] (ab203491), Abcam;
[0047] Phospho-p38 MAPK(Thr180 / Tyr182)Antibody#9211,CST;
[0048] p38 MAPK Antibody #9212, CST;
[0049] Phospho-p44 / 42MAPK(Erk1 / 2)(D13.14.4E) Rabbit mAb #4370, CST;
[0050] p44 / 42MAPK(Erk1 / 2)(137F5)Rabbit mAb#4695,CST;
[0051] Phospho-NF-κB p65(Ser536)(93H1)Rabbit mAb#3033,CST;
[0052] NF-κB p65(C22B4)Rabbit mAb#4764,CST;
[0053] Anti-rabbit IgG,HRP-linked Antibody#7074,CST;
[0054] Anti-mouse IgG,HRP-linked Antibody#7076,CST.
[0055] 4. m6A Dot Blot Detection in Mouse Brain Tissue and Cells
[0056] Add 1 mL of TRIzol to fresh tissues or cells, vortex until fully lysed, and let stand at room temperature for 5 min; add 0.2 mL of chloroform per mL of TRIzol, cover the tube tightly and shake vigorously for 15 seconds, and incubate at room temperature for 2-3 minutes; centrifuge at 4°C, 12000g for 15 minutes, the mixture is separated into three phases, carefully transfer the upper aqueous phase to a new Eppendorf tube, taking care not to disturb the middle layer; add 0.5 mL of isopropanol per mL of TRIzol to precipitate RNA, invert to mix, and incubate at room temperature for 10 minutes; centrifuge at 12000g for 10 minutes to collect the RNA precipitate; wash the RNA precipitate once with 75% ethanol, add at least 1 mL of 75% ethanol per mL of TRIzol, vortex to mix the sample solution, and centrifuge at 4°C 7500g for 5 minutes; repeat the wash once; completely remove the ethanol, air dry or vacuum dry the RNA precipitate for 10 minutes; dissolve the RNA with 50 μL of RNase free water, and gently pipette repeatedly to obtain total RNA. The RNA concentration of different treatment groups was adjusted to be consistent, and the samples were quickly spotted on the nitrocellulose membrane, and then irradiated and cross-linked under 302nm UV light for 30min; after cross-linking, the membrane was washed with TBST buffer for 5min; blocked with protein-free rapid blocking solution at room temperature for 30min, and incubated with primary antibody (m6A antibody-202003, SYSY) at 4℃ overnight; washed 3 times in TBST buffer, 10min each time, incubated with corresponding species secondary antibody at room temperature for 1h, and washed 3 times in TBST buffer, 10min each time. ECL development was performed with ECL colorimetric solution. Methylene blue quantification of nucleic acid: Take a membrane treated in the same way, add an equal volume of sample, and after UV cross-linking, perform methylene blue staining, place the membrane in the solution for staining for 10min, wash with TBST buffer for 10min, change TBST buffer several times during the period, and take pictures.
[0057] 5. Single-cell sequencing analysis
[0058] Transfer the tissue to be tested to a 100×20mm cell culture dish, grab the blade with an elbow hemostatic forceps, chop the tissue, and remove non-target tissues such as obvious blood vessels and meninges. The final tissue fragments should be about 1-3mm. Then divide the tissue into 50mL centrifuge tubes so that the tissue in each tube does not exceed 5mL, add preheated STEMxyme I and deoxyribonuclease I digestion solution, and add 5mL for every 1mL of tissue. Seal the centrifuge tube cap with sealing film and incubate with rotation at 37℃ for 20min. After incubation, use a 10mL serological pipette to gently blow the sample up and down until the tissue clumps are completely dissolved into a cell suspension. Then pass the cell suspension through a 100μm sieve, collect it in a new 50mL centrifuge tube, and add precooled HBSS buffer to make the volume reach 25mL. Slowly add 25mL of 1.8M sucrose solution to the above cell suspension and invert to mix. This step will form a 0.9M sucrose gradient. Centrifuge without brake for 10 min (800×g, 4°C). Carefully aspirate the myelin fragments and as much sucrose solution as possible, and then wash the sample with pre-cooled HBSS without calcium and magnesium. Then resuspend it in HBSS containing 5% FBS, take an appropriate amount of the suspension and add it to the staining buffer (AO / PI or trypan blue) for counting quality control analysis.
[0059] ①10×Isolate single cells: Chromium TMSingle Cell 3'Solution is a microfluidic platform based on Gem Code technology. Gel beads with barcodes and primers are encapsulated with single cells in oil droplets to form GEM (Gelbead in emulsion). GEM refers to a mixture of Gel beads containing barcodes, cells, and reaction reagents encapsulated in oil droplets. Among them, the primer composition is the full-length Illumina Tru-Seq Read 1 sequencing primer, 16bp 10X Barcode sequence (used to distinguish cells), 12bp unique molecular identifier (UMI) (to distinguish different transcripts of the same cell and remove PCR Duplications), and 30bp poly dT reverse transcription primer. The prepared cell suspension, 10×Barcode gel beads and oil droplets are added to different lanes of Chromium Chip B (a total of 8 lanes) respectively, and GEM is formed through the microfluidic "double cross" cross system. In order to obtain a single-cell reaction system, the concentration of the cell suspension is controlled at 700-1200 cells / μl, so 90-99% of the generated GEMs do not contain cells, and most of the remaining GEMs contain one cell. ②cDNA formation and amplification reaction: the gel beads in the GEM are dissolved, the cells are lysed to release mRNA, and the barcoded cDNA for sequencing is generated by reverse transcription; after the liquid oil layer is destroyed, the cDNA amplification reaction is carried out, and the quality inspection is carried out after purification. After the quality inspection is qualified, the library is constructed. ③Library construction: enzyme cutting and interruption, the fragments are end-filled, and base A is added, the adapter is connected, the kit screens and recovers the target size fragments, and the library is quality inspected and quantified. ④Library sequencing: the constructed library structure from left to right (5'~3') is: Illumina P5 adapter, P5 sequencing primer (black Read1), 16bp Barcode, 12bp UMI, ploy (dT) VN sequence, inserted cDNA fragment, P7 sequencing primer (black Read2), sample Index (i7 index read), Illumina P7 adapter. Read1 has a sequence length of 28bp (16bp Barcode + 12bp UMI), which is used to distinguish cells and different transcripts (mRNA) of each cell; Read2 has a sequence length of 91bp, which is used to compare the reference genome to determine gene information. ⑤ Sequencing analysis to screen the expression of specific genes in different cell subpopulations: We first used the 10×Genomics official analysis software package Cell Ranger to filter, align, quantify, and identify the recovered cells of the raw data, and finally obtained the gene expression matrix of each cell.Subsequently, Seurat (https: / / satijalab.org / seurat / ) was used for further cell filtering, standardization, cell subpopulation classification, differentially expressed gene analysis of each subpopulation, and marker gene screening. Finally, 29 cell subtypes were found in the damaged brain tissue of the TBI model. According to the CellMarker database (http: / / bio-bigdata.hrbmu.edu.cn / CellMarker / ), we classified and analyzed the 29 cell subtypes.
[0060] 6. Immunofluorescence Staining
[0061] The frozen sections or cell slides were dried at room temperature for 15 minutes, and the staining range was circled with an immunohistochemistry pen, and washed with PBS for 10 minutes; the membrane was broken with PBS containing 0.3% TrixtonX-100 for 10 minutes, and washed with PBS three times, each time for 10 minutes; blocked with PBS containing 10% bovine serum albumin for 1 hour at room temperature; the corresponding primary antibody was added and incubated at 4°C overnight; washed with PBS three times, each time for 10 minutes; the corresponding fluorescent secondary antibody was added and incubated at room temperature for 1 hour; washed with PBS three times, each time for 10 minutes; after sealing with DAPI anti-quenching sealing agent, the results were observed under a fluorescence microscope and photographed.
[0062] Antibody reagents used are as follows:
[0063] Anti-ALKBH5 Antibody(ABE547),Millipore;
[0064] AIF-1 / Iba1 Antibody (NB100-1028), Novusbio;
[0065] Anti-Glial Fibrillary Acidic Protein(GFAP)Antibody(AB5804),Millipore;
[0066] Recombinant Anti-NeuN antibody [EPR12763]-Neuronal Marker (ab177487), Abcam;
[0067] Donkey anti-Rabbit IgG(H+L)Highly Cross-Adsorbed Secondary Antibody,Alexa Fluor TM 488(A-21206), Invitrogen;
[0068] Donkey anti-Mouse IgG(H+L)Highly Cross-Adsorbed Secondary Antibody,Alexa Fluor TM 488(A-21202), Invitrogen;
[0069] Donkey anti-Rabbit IgG(H+L)Highly Cross-Adsorbed Secondary Antibody,Alexa Fluor TM 594(A-21207), Invitrogen;
[0070] Donkey anti-Mouse IgG(H+L)Highly Cross-Adsorbed Secondary Antibody,Alexa Fluor TM 594(A-21203), Invitrogen;
[0071] Goat anti-Rat IgG(H+L)Cross-Adsorbed Secondary Antibody,AlexaFluor TM 488(A-11006), Invitrogen;
[0072] Donkey anti-Goat IgG(H+L)Cross-Adsorbed Secondary Antibody,AlexaFluor TM 594(A-11058), Invitrogen.
[0073] 7. Obtaining Primary Microglia from Mice and Rats and Cultivating the BV2 Cell Line
[0074] The brain tissues of SD rats and C57 mice at 1-3 days old were removed from the skull, and the cortical tissues were separated after peeling off the meninges under a microscope; they were digested with 0.125% trypsin at 37°C for 2 minutes, placed in a 0.01% PDL-coated culture bottle, and cultured in DMEM complete medium containing 10% heat-inactivated fetal bovine serum (FBS) and 100U / ml penicillin / streptomycin in an incubator at 37°C, 5% CO2 for 2 weeks; the culture medium was replaced 1 day after primary isolation, and then replaced every 2-3 days; after 14 days, microglia were separated by shaking at 180rpm for 30 minutes on a 37°C rotary shaker, and the microglia in the supernatant were collected for subsequent experiments. Mouse microglial cell line BV2 was cultured in DMEM complete medium containing 10% heat-inactivated fetal bovine serum (FBS) and 100 U / ml penicillin / streptomycin in an incubator at 37°C and 5% CO2. After the cells entered the logarithmic growth phase, the cells were collected for subsequent experiments.
[0075] 8. Cell qPCR detection
[0076] Add 1 mL of TRIzol to fresh tissues or cells, vortex until fully lysed, and stand at room temperature for 5 minutes; add 0.2 mL of chloroform per mL of TRIzol, cover the tube tightly and shake vigorously for 15 seconds, and incubate at room temperature for 2-3 minutes; centrifuge at 4°C, 12000g for 15 minutes, the mixture is divided into three phases, carefully transfer the upper aqueous phase to a new Eppendorf tube, and be careful not to disturb the middle layer; add 0.5 mL of isopropanol per mL of TRIzol to precipitate RNA, invert and mix, and incubate at room temperature for 10 minutes; centrifuge at 12000g for 10 minutes to collect RNA precipitate; wash the RNA precipitate once with 75% ethanol, add at least 1 mL of 75% ethanol per mL of TRIzol, vortex to mix the sample solution, and centrifuge at 4°C 7500g for 5 minutes; repeat the wash once; completely remove the ethanol, air dry or vacuum dry the RNA precipitate for 10 minutes; dissolve the RNA with 50 μL of RNase free water, and gently pipette repeatedly to obtain total RNA. Use an RNA reverse transcription kit to reverse transcribe the extracted total RNA into cDNA. Use the qPCR kit, configure the system according to the instructions, add the corresponding primers and cDNA template, use the qPCR instrument to detect, read the CT value, and analyze the results.
[0077] 9. Breeding of Microglia-specific ALKBH5 Knockout Mice
[0078] ALKBH5 has two transcripts, Alkbh5-201: Transcript ID-ENSMUST00000044250.4 and Alkbh5-202: Transcript ID-ENSMUST00000134770.2 (from the Bioconductor database). After analyzing its structure, we selected the Alkbh5-201 transcript and used CRISPR / Cas9 gene editing technology to insert Loxp (locus of X-over P1) Cre enzyme cleavage sites at both ends of the exon1-exon2 region, and obtained a homozygous (ALKBH5) with two loxP sites by heterozygous interpairing. flox / flox ) mice. ERT2 The tool mice were mated and bred, and tamoxifen was induced to finally obtain microglia-specific ALKBH5 gene knockout mice (ALKBH5 MG-KO ).
[0079] 10. Tar violet staining and Evens Blue staining
[0080] Tar violet staining: Tar violet staining is used to assess the damage to the cranial cortex after TBI. Weigh 1g of tar violet powder, add deionized water to 1000ml, mix thoroughly and dissolve, adjust the pH to 3.7 with glacial acetic acid, and set aside. Take out the frozen sections stored at -80℃, place them on a shelf and blow dry them thoroughly, then immerse the brain slices in tar violet staining solution for staining (the specific time is adjusted according to actual conditions). After staining is completed, recover the tar violet staining solution, rinse the brain slices with running water for about 1h (the rinsing time is adjusted according to the degree of staining of the brain slices) to remove excess staining solution residues. Finally, take out the brain slices and blow dry them, scan the images with a scanner, and set the resolution to 600dpi.
[0081] Evens Blue staining: The changes in microvascular permeability after TBI were evaluated by measuring the amount of Evens Blue dye leakage. The mice to be tested were anesthetized with 5% chloral hydrate, and 4 ml / kg of 2% Evens Blue dye was injected from the jugular vein. After 2 hours of circulation in the body under anesthesia, the chest was opened, the heart was fully exposed, the aorta was clamped with hemostatic forceps, the perfusion needle was inserted into the apex of the heart, the right atrial appendage was cut open, the venous blood was opened, and 40 ml of pre-cooled PBS solution was perfused. After successful perfusion, the brain was removed and a 2 mm thick brain slice was made with the cortical injury focus as the boundary.
[0082] 11. Neurobehavioral function assessment test
[0083] Before TBI modeling and 1, 3, 7, and 14 days after modeling, researchers used a double-blind method to evaluate the changes in the neurobehavioral function of mice. The evaluation items and methods are as follows:
[0084] A. The modified Neurological Severity Score (mNSS) is used to evaluate the comprehensive evaluation system of neurobehavioral function in mice after TBI. (The score ranges from 0 to 12, with 0 representing normal and 12 representing the most severe neurological deficit). The scoring items and scoring rules are as follows:
[0085] 1) Motor function assessment (6 points in total)
[0086] A) Lift the mouse's tail and let it hang in the air, and observe (3 points in total)
[0087] The forelimb on the side opposite to the injury is unable to bend toward the abdomen.
[0088] The hind limb on the side opposite to the injury is unable to bend toward the abdomen.
[0089] The head deflects more than 10° to the side opposite to the injury within 30 seconds.
[0090] B) Place the mouse on a spacious platform and observe the mouse crawling (3 points in total)
[0091] Normal crawl 0
[0092] The limbs on the opposite side of the injury are weak and cannot crawl straight.
[0093] The limbs on the opposite side of the injury are weak and move around the hemiplegic side.
[0094] Falling to the hemiplegic side, difficulty crawling 3
[0095] 2) Balance function assessment (6 points in total): place the mouse on a balance beam and observe whether the mouse can crawl flexibly and steadily on the balance beam.
[0096] Occasional instability when crawling on the balance beam1
[0097] During crawling, the forelimb or hindlimb on the side opposite to the injury falls off the balance beam
[0098] During the crawling process, the front and back limbs on the opposite side of the injury fell off the balance beam or held the balance beam and rotated for more than 30 seconds 3 Try to balance, but the mouse fell off the balance beam within 20-30 seconds 4
[0099] The mouse attempted to balance, but fell off the beam within 10-20 seconds.
[0100] The mouse attempted to balance, but fell off the beam 6 times within 10 seconds.
[0101] B. Rotarod Test
[0102] Used to evaluate changes in sensorimotor coordination and motor learning ability of mice after TBI. The test requires mice to maintain balance on a uniformly rotating rod, and records their movement time on the rod and the rotation speed of the rod when they fall. Training was conducted for 3 consecutive days before modeling, 3 times a day. Place the mouse on the rod to adapt for 1 minute, then start the rod, rotating at a constant speed of 20 rpm, and train for 5 minutes. If the mouse falls, put the rod back until the movement time reaches 5 minutes. On the third day of training, a baseline test was performed after 2 training sessions. The rod accelerated from 0 until it rotated at a constant speed of 40 rpm, and the time when the animal fell was recorded. If the mouse hugged the rod for 2 laps without moving, it was also considered to have fallen. The test of mice after modeling is the same as the baseline test. Clean the instrument with alcohol after training or testing and wipe it dry.
[0103] C. Hanging Wire Test
[0104] Used to evaluate changes in neuromuscular injury and motor coordination in mice after TBI. The center of the wire is used as the starting point, and the timing begins when the mouse holds the wire with only its two forelimbs. The entire test lasts for 180 seconds. The time is recorded when the mouse crawls to the end of either end of the wire or falls from the wire. The mouse is suspended in the center of the wire again and the test begins. During the test, each arrival or fall of the mouse and its time point must be recorded. [Standing on the hind legs, facing down; balancing on the wire - need to be put back to the original position and continue to start] Result calculation: ① "Fall" score starts from 10 points, and one point is subtracted for each fall; "Arrival" score starts from 0 points, and one point is added for each arrival at the end. Finally, the average score of "Fall" and "Arrival" is recorded. ② Record the longest hanging time or average hanging time of the mouse.
[0105] D. Grip Strength test
[0106] An essential tool for studying animal activity, motor control, and coordination, the grip strength test is a simple, non-invasive method that aims to assess limb movement or muscle function in rodents. It measures neuromuscular function by determining the maximum peak force generated by the animal. The test device consists of a bar or grid connected to a force sensor that records the maximum force obtained in each trial. The force sensor is connected to a computer. 1) Mouse forelimb grip strength test: Place the experimental mouse on the grip dynamometer and gently pull the mouse's tail to make the mouse grab the probe with its forelimbs. When the experimenter applies the maximum force to the experimental mouse, record the reading on the grip dynamometer. Repeat the measurement multiple times to ensure the result. 2) Mouse hindlimb grip strength test: Place the experimental mouse on the grip dynamometer and let its hind limbs grasp the probe. Gently pull the mouse's tail to make it grasp the probe with force. Record the grip dynamometer reading when the experimental mouse applies the maximum force. Repeat the measurement multiple times.
[0107] E. VisuGait animal gait analysis
[0108] Through the footprint light refraction technology, a high-speed camera is used to collect the footprint information of the moving mice during their walking process, and then the footprint gait analysis system independently developed by Shanghai Xinruan is used to automatically identify and analyze the gait indicators of the mice to evaluate the movement and spatial learning ability of the mice. The evaluation indicators include: ground contact area, swing speed, swing duration, braking duration, walking cycle, front and rear limb step width, normal step sequence ratio, etc., so as to objectively evaluate the gait changes of the model mice.
[0109] Preparation before behavioral testing:
[0110] Adapt to the environment in advance: Place the mice in the test environment two days in advance (it is best to place the equipment in the breeding environment for testing). After changing the environment, the mice will show anxiety due to changes in the direction of the air-conditioning outlet, the position of the light, the environmental smell, etc.
[0111] Equipment debugging: Gait uses the light refraction technology of footprints. It is recommended that the experimenter debug the equipment one day in advance at the same time period as the experiment is expected to be carried out.
[0112] Pre-test training: Pre-test training for gait analysis is necessary. Place the experimental mice on the gait track. For the first time on the track, place the mice in the same cage on the track for 5-10 minutes. Keep the environment quiet and do not test. When the mice pass through the channel, they will remember that there is an exit to return to the cage and stay with their companions. This will be the motivation for the mice to actually pass through the channel. Then place the experimental mice at one end of the track, block the other end with a baffle, and wait in front of the computer for the mice to enter the video area to start recording.
[0113] Formal experiment: Use a baffle to block the passage back to the exit of the mouse cage, place the experimental mouse at the entrance of the passage, return to the computer and wait for the mouse to pass through the camera test area. Do not try to repeatedly place the mouse in the same position to start, and then take it back to the starting point after passing through the passage. Repeated operations like this will cause the mouse to mistakenly think that its behavior is wrong, causing it to stay longer. Just place the mouse at the entrance, and then wait for the mouse to walk back and forth on the glass plate and make a record. It is recommended to measure each mouse more than 5 times to ensure clear image records. Collect multiple consecutive walks of each mouse and average these walks to reduce experimental errors.
[0114] (II) Implementation plan and results
[0115] In this example, a TBI model of C57BL / 6J mice was first established by controlled cortical impact (CCI), and RNA and protein of damaged cortical tissues at different time points after modeling were collected. m6ADotblot and Western blot detection revealed that with the passage of time after modeling, the m6A modification level of damaged cortical tissue transcriptome showed a certain degree of downward trend, which may be related to the gradual increase in protein expression of demethylase ALKBH5. The results are shown in Figure 2. Figure 1 As shown, Figure 1 A shows the Western blot test results of m6A-modified key regulatory proteins in damaged cortical tissue at different modeling time points. Compared with the sham operation group (Sham), the expression of demethylase ALKBH5 in TBI damaged cortical tissue gradually increased over time; Figure 1 B shows the Dot blot detection results of the m6A modification level of the damaged cortical tissue transcriptome at different modeling time points. Compared with the sham operation group (Sham), the m6A modification level of the TBI damaged cortical tissue transcriptome decreased over time.
[0116] Furthermore, in order to better study the cell subtypes affected by ALKBH5 demethylation and the related functional localization, this example analyzed the transcriptome single-cell sequencing results of damaged cortical tissue at different time points after modeling and found that ALKBH5 was mainly expressed in microglia, astrocytes and neurons. By immunofluorescence co-localization of ALKBH5 protein expression in damaged cortical brain tissue of modeling mice with the above three cell subtype-specific markers, it was found that ALKBH5 was mainly co-stained with IBA1 in the damaged cortical area. The results are as follows: Figure 2 As shown; Figure 2A is a schematic diagram of the single-cell sequencing results of the damaged cortical tissue after CCI modeling in mice. The damaged cortical tissues of the sham operation group (Sham, n=3), the first day after injury (TBI-1, n=4), the third day (TBI-3, n=2), the seventh day (TBI-7, n=3) and the fourteenth day (TBI-14, n=4) after modeling were collected and mixed, and then single-cell sequencing was performed to analyze the number of cells captured at different time points; Figure 2 B is the result of tSEN dimensionality reduction analysis after cell type identification through the expression results of cell-specific gene markers; Figure 2 C is the t-SNE dimension reduction distribution diagram of transcriptome expression of ALKBH5 at the single cell level; Figure 2 D is a violin analysis of transcriptome expression of ALKBH5 at the single-cell level; Figure 2 E is the immunofluorescence co-localization staining result of ALKBH5 with neuron-specific marker NEUN, astrocyte-specific marker GFAP and microglia-specific marker IBA1. The Sham group selected the edge of the normal cortical tissue of the sham operation group for photography, and the TBI group selected the relatively intact area of the inner cell structure of the damaged cortical tissue and the edge of the damaged cortical tissue for photography. The above results show that ALKBH5's m6A demethylation modification at the transcriptome level of damaged cortical tissue after TBI may mainly occur in microglia. Therefore, the subsequent in vitro analysis and verification will focus on the regulatory function of m6A modification in microglia.
[0117] Furthermore, lipopolysaccharide (LPS) was used to treat the drug and construct an inflammatory activation model of BV2 cell line, rat and mouse primary microglia in vitro. On this basis, the expression of ALKBH5 in microglia was downregulated by siRNA knockdown technology, and the biological activity of ALKBH5 and its potential regulatory function on microglia under different treatment conditions were observed. The experimental results showed that after LPS-induced inflammatory activation of microglia, the demethylase ALKBH5 had a more obvious increase in expression and nuclear translocation, the intracellular transcriptome m6A modification level decreased, and the expression of inflammatory-related factors increased. Although downregulating the expression of ALKBH5 can restore the intracellular transcriptome m6A modification level to a certain extent, it further increases the expression of inflammatory-related factors induced by LPS, exacerbating the inflammatory activation effect of microglia, such as Figure 3 As shown; Figure 3 A is the result of Western blot, which shows that after in vitro lipopolysaccharide (50 ng / ml, LPS) drug treatment, the expression of ALKBH5 in BV2 cell line, mouse and rat primary microglia increased to varying degrees; Figure 3B is the result of down-regulating the expression of ALKBH5 in BV2 cell line, primary microglia of mice and rats by siRNA and detecting cell activity by CCK-8; Figure 3 C is the result of down-regulating the expression of ALKBH5 in BV2 cell line, primary microglia of mice and rats by siRNA after 6 hours of LPS treatment in vitro, and detecting the protein level of ALKBH5 by western blot after 36 hours; Figure 3 D is the result of Dot-blot detection of m6A modification levels in BV2 cell lines, primary microglia of mice and rats after LPS drug treatment in vitro combined with siRNA down-regulation of ALKBH5 expression; Figure 3 E is the result of double immunofluorescence staining of IBA1 (red) and ALKBH5 (green) on three types of microglia after LPS treatment in vitro combined with siRNA to downregulate the expression of ALKBH5, and the nuclei were confirmed by DAPI (blue) staining; Figure 3 F is the result of Real-time PCR detection of the changes in the relative expression levels of inflammatory factor mRNA in the three types of microglia before and after LPS drug treatment in vitro combined with siRNA to downregulate ALKBH5 expression.
[0118] The increased expression of ALKBH5 has a certain inhibitory effect on the inflammatory activation of microglia. To further verify that ALKBH5 also has an effect on the inflammatory activation of microglia in vivo, microglia-specific ALKBH5 gene knockout mice were constructed using CRISPR / Cas9 gene editing technology. After TBI modeling of these mice, it was found that compared with negative control mice in which ALKBH5 expression was not knocked out, microglia-specific ALKBH5 gene knockout mice showed more obvious nervous system damage and their neurobehavioral recovery was slower, such as Figures 4-5 As shown; among which:
[0119] Figure 4 A is the breeding strategy of microglia-specific ALKBH5 gene knockout mice. Figure 4 B is an overview of the in vivo experiments and neurobehavioral testing time. Figure 4 C is a comparison of the cortical tissue damage of mice at different time points after CCI modeling. It can be seen that ALKBH5 was upregulated at 7 days (TBI-7) and 14 days (TBI-14) after modeling. MG-KO Cortical tissue damage and repair in mice compared with ALKBH5 MG-Con The group was relieved, and the local cortical tissue cavitation was more obvious; Figure 4D is the gross pathological changes of the brain tissue of the model mice in the coronal sections stained with tar violet. Compared with the contralateral cortex tissue, ALKBH5 MG-KO The Ipsilateral Cortex of mice was significantly more missing than that of the control group (ALKBH5 MG-Con ) is more obvious; Figure 4 E is a comparison of EB dye extravasation in mouse cortical tissue at different time points after modeling. The blue area represents the location of dye leakage. The statistical results show that ALKBH5 MG-KO The repair of the blood-brain barrier in the injured cortical tissue of mice was delayed, and the leakage of EB dye was more severe than that of ALKBH5 MG-Con The group is more obvious; Figure 4 FI is the neurobehavioral function score of mice at different time points after modeling, including mNSS scores ( Figure 4 F), Rotarod test( Figure 4 G), Hanging Wire test( Figure 4 H) and Grip Strength Test( Figure 4 I).
[0120] Figure 5 AD is ALKBH5 MG-KO Mouse, ALKBH5 MG-Con The statistical results of basic movement data of mice and their sham-operated counterparts in gait detection analysis showed that after CCI modeling, ALKBH5 MG-KO ALKBH5 MG-Con Compared with the sham operation group, the number of steps per unit time ( Figure 5 A), walking speed ( Figure 5 B), the distance traveled by the left limb between two consecutive starting positions ( Figure 5 C) and the distance traveled by the right limb between two consecutive starting positions ( Figure 5 D) significant functional decline occurs; Figure 5 E is the statistical results of footprint pressure data of four groups of mice in gait detection analysis, ALKBH5 MG-KO The footprint pressure of mice after modeling was higher than that of ALKBH5 MG-Con Mice were significantly weakened; Figure 5 F is the heat map analysis results of footprint pressure in the four groups of mice in gait detection analysis. It can be seen that ALKBH5 MG-KO Mice and ALKBH5 MG-Con The footprint pressure of the left limb of the mouse was significantly weaker than that of the right limb; Figure 5GJ are the results of left forelimb gait detection and analysis of four groups of mice. MG-KO The average footprint pressure of the left forelimb of mice after modeling ( Figure 5 G), average contact area with the ground ( Figure 5 H), the maximum contact area between a single foot and the ground ( Figure 5 J) Compared with ALKBH5 MG-Con The mice showed a significant decrease in the maximum pressure of a single footprint ( Figure 5 I) had no significant statistical difference; Figure 5 KN are the results of the left hind limb gait test and analysis of the four groups of mice. MG-KO The average footprint pressure of the left hind limb of mice after modeling ( Figure 5 K), average contact area with the ground ( Figure 5 L), single footprint maximum pressure ( Figure 5 M) compared to ALKBH5 MG-Con There was no significant statistical difference in mice, but the maximum contact area between the left hind limb and the ground ( Figure 5 N) is higher than ALKBH5 MG-Con Mice were weakened.
[0121] The above results prove both in vivo and in vitro that ALKBH5, as an m6A demethylase, can affect the disease progression of TBI patients by regulating microglial neuroinflammatory responses. This provides a new target for how to effectively curb excessive inflammatory activation responses in microglia and promote neurological function repair and prognosis in TBI patients in the future.
[0122] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.
Claims
1. Application of demethylase ALKBH5 as a target in the preparation or screening of drugs for the treatment of neuroinflammation after traumatic brain injury.
2. The use according to claim 1, characterized in that The application includes preparing a drug for treating neuroinflammation after traumatic brain injury by using a substance that specifically promotes or activates the expression or activity of ALKBH5.
3. The use according to claim 2, characterized in that The substances that promote or activate the expression or activity of ALKBH5 include ALKBH5 recombinant protein, nucleic acid molecules that can specifically increase the expression of ALKBH5 gene, and recombinant vectors or recombinant bacteria containing the nucleic acid molecules.
4. A method for experimentally verifying the use of ALKBH5 in inhibiting neuroinflammation after traumatic brain injury or downregulating the expression of ALKBH5 in microglia in promoting neuroinflammation after traumatic brain injury for non-diagnostic treatment purposes, characterized in that: The following steps are involved: Step 1. Detect the expression of ALKBH5 and the m6A modification level of the transcriptome: Western blot was used to detect the differentially expressed proteins in the TBI-injured cortical tissue at different time points after the TBI mouse model was established, and Dot blot was used to detect the m6A modification level of the transcriptome in the TBI-injured cortical tissue at different time points after the model was established; Step 2. Single-cell sequencing analysis of ALKBH5 expression and localization: Analyze the transcriptome single-cell sequencing results of damaged cortical tissue at different time points after TBI mouse model establishment to detect the expression and localization of ALKBH5 in TBI damaged cortical tissue; Step 3. Detect the regulatory effect of ALKBH5 on microglial inflammation induced by traumatic brain injury: Use lipopolysaccharide (LPS) drug treatment to construct an inflammatory activation model of BV2 cell line, rat and mouse primary microglia in vitro, then knock down the expression of ALKBH5 in microglia by siRNA, and observe the biological activity of ALKBH5 under different treatment conditions and its regulatory function on microglial inflammation; Step 4. Detect in animals the promoting effect of microglia-specific ALKBH5 gene knockout on neuroinflammation after TBI: construct microglia-specific ALKBH5 gene knockout mice by CRISPR / Cas9 gene editing technology, and use mice without ALKBH5 expression as negative control group. After TBI modeling was established in both groups of mice, the neurobehavioral function of the mice after modeling, the damage of the cortical tissue of the mice at different time points after modeling, the overall pathological changes of the continuous coronal sections of the mouse brain tissue tar violet staining, and the leakage of EB dye in the cortical tissue of the mice at different time points after modeling were detected.
5. The use according to claim 2, characterized in that The method for constructing microglia-specific ALKBH5 knockout mice in step 5 comprises: after analyzing the structure of ALKBH5, using CRISPR / Cas9 gene editing technology to insert LoxP (locus of X-over P1) Cre enzyme cleavage sites at both ends of the exon1-exon2 region of the transcript Transcript ID-ENSMUST00000044250.4 of the ALKBH5 gene, and obtaining homozygous ALKBH5 with two loxP sites by heterozygous interpairing. flox / flox Mice, and then homozygous ALKBH5 flox / flox Mice with microglia-specific CX3CR1-Cre ERT2 The tool mice were mated and bred, and tamoxifen was induced to finally obtain microglia-specific ALKBH5 gene knockout mice ALKBH5 MG-KO .
6. Application of a microglia-specific ALKBH5 gene knockout mouse model in studying the regulatory effect of ALKBH5 on neuroinflammation after traumatic brain injury and in constructing a model for studying the function of the ALKBH5 gene, characterized in that: The method for constructing the ALKBH5 gene knockout mouse model comprises: after analyzing the structure of ALKBH5, using CRISPR / Cas9 gene editing technology to insert LoxP (locus of X-over P1) Cre enzyme cutting sites at both ends of the exon1-exon2 region for the transcript Transcript ID-ENSMUST00000044250.4 of the ALKBH5 gene, and obtaining a homozygous ALKBH5 with two loxP sites by heterozygous interpairing. flox / flox Mice, and then homozygous ALKBH5 flox / flox Mice with microglia-specific CX3CR1-Cre ERT2 The tool mice were mated and bred, and tamoxifen was induced to finally obtain microglia-specific ALKBH5 gene knockout mice ALKBH5 MG-KO .
